Our therapeutics pipeline includes anti-viral drug compounds such as QN-165 (formerly referred to as AS1411), cancer drug compounds such as QN-247 (formerly referred to as AS1411-GNP or ALAN), and RAS-F, as well as STARS, a DNA/RNA-based treatment device.

To learn more about partnering or licensing opportunities, please contact partnering@qualigeninc.com

Select a drug candidate to learn more

ProgramDiscoveryPreclinicalPhase 1Phase 2
QN-165
COVID-19
QN-247
AML
RAS-F
STARS
IndicationStage
QN-165 Phase 1
QN-247 Preclinical
RAS-F Preclinical
STARS Discovery
QN-165QN-247RAS-FSTARSProgram
Discovery
Preclinical
Phase 1
Phase 2

QN-165 was studied in over 100 patients to treat AML and renal cell carcinoma in pre-Qualigen clinical trials.
QN-165 has potential to be broad based antiviral with COVID-19 as initial condition.